The Claim

In mice fed a high-fat diet, treatment with GW501516 is associated with increased hepatic levels of 16:0/18:1-phosphatidylcholine, an endogenous ligand for PPARα, which may enhance PPARα activation and promote downstream fat oxidation.

Source: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In mice on a high-fat diet, a drug called GW501516 might boost a specific fat in the liver that could help turn on a fat-burning switch, making the body burn fat more efficiently.

See the scientific wording

In mice fed a high-fat diet, GW501516 treatment is associated with increased hepatic levels of 16:0/18:1-phosphatidylcholine, an endogenous ligand for PPARα, which may enhance PPARα activation and downstream fat oxidation.

What the research says

1 study

  1. Study: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

    The study shows that the drug GW501516 raises a specific fat molecule in the liver that helps turn on a fat-burning switch, which matches what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.